MSD Ireland invests over €1 billion in Dunboyne and Carlow plants

Healthcare company MSD Ireland has today announced the official opening of a new, state-of-the-art site in Dunboyne in addition to a significant expansion at its Carlow site.

The projects represent a recent investment of over €1 billion across both facilities.

The expansion projects have led to the creation of 670 new jobs across both sites, further building on the company's successful recruitment drive in recent years and bringing total employee numbers in Ireland to over 3,100 people.

Active recruitment is currently ongoing for over 100 jobs, offering a wide range of important roles in engineering, science, manufacturing operations, quality and more.

MSD Dunboyne in Co. Meath is MSD’s first biologics drug substance single use commercialisation facility, playing an important role in helping to commercialise key medicines. Furthered by this most recent investment, the cutting-edge innovation and collaboration between MSD Dunboyne’s research and manufacturing teams will significantly accelerate the time it takes to bring a medicine to market for the benefit of patients around the world.

MSD Carlow serves as a filling site for the launch and commercial supply of vaccines, biologics, and small molecule drug products. Established in 2008, this state-of-the-art facility was MSD's first vaccines operation outside of the United States and has seen significant growth, expansion, and investment since first opening its doors. The new expansion will strengthen MSD’s global manufacturing capabilities to meet increased demand for MSD’s medicines and vaccines.

Speaking about the announcement, Taoiseach Leo Varadkar TD said: “This is fantastic news for counties Meath and Carlow with the opening by MSD of its new state of the art facility in Meath and the expansion of its Carlow site. The €1 billion investment by MSD is creating 670 jobs and expanding the company’s operations. It reinforces the Government’s commitment to balanced regional development, and further enhances Ireland’s global status in the pharmaceutical sector.”

Eva Gallagher, Site Lead at MSD Dunboyne, said: "Today marks a significant milestone in MSD Dunboyne's journey as we officially open our new, state-of-the-art facility. At MSD, our focus is always on the patient and by harnessing the expertise and synergy between our exceptional research and manufacturing teams, we are not only shortening the timeline for drug development but also creating healthier, happier futures for patients worldwide."

Details on open roles at MSD Ireland are available at https://jobs.msd.com/ireland